ERBB2 and breast cancer: The observations on the use and impact of the Oncotype DX Breast Recurrence Score test on the participating reference centers of PONDx in Italy support the notion that the test provides clinically useful predictive information, complementing standard clinical and pathological risk parameters for patients with HR+, HER2− N0/N1 primary BC.